Bundle 5 (IC 2027)

Only available as part of a package

If you are seeing this page, then you are not signed in or have not yet enrolled in the City of Hope Self-Directed Intensive Course in Genomic Cancer Risk Assessment.
To return the course homepage, click the button below.

HOMEPAGE

If you need assistance, contact us at [email protected].

Key:

Complete
Failed
Available
Locked
Clinical Management of Hereditary Breast Cancer
Open to view video.  |  67 minutes
Open to view video.  |  67 minutes • Review the tools for high-risk breast and ovarian cancer screening • Identify the role and efficacy of breast and ovarian cancer surgical risk reduction • Recognize the role of chemoprevention options for breast and ovarian cancer risk reduction • Use evidence-based guidelines to inform risk management recommendations for patients with pathogenic variants in high or moderate penetrance breast and ovarian cancer susceptibility genes • Apply individualized screening and risk management options and recommendations to case examples
You must register to access.
ICSD 2026 - Bundle 5 Quiz
4 Questions  |  Unlimited attempts  |  5/6 points to pass
4 Questions  |  Unlimited attempts  |  5/6 points to pass Select the appropriate response for each question. Correct responses will display after a passing score of 80% (6/7) is reached. Please retake the quiz until you pass.
You must register to access.
Bundle 5 Distance Learning Evaluation
4 Questions
4 Questions Please respond to the statements in this evaluation as they relate to your experiences with this week's distance learning modules. This survey will take less than 3 minutes to complete.
You must register to access.
Elective Modules
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 1
Open to view video.  |  49 minutes
Open to view video.  |  49 minutes Review NCCN guidelines for high-risk cancer screening and management. Identify the methods and efficacy of breast and gynecologic screening tools. Identify the methods and efficacy of breast and ovarian surgical risk reduction. Understand the potential impact of cancer risk assessment and genetic testing related to surgical decision-making and timing. Recognize emerging role of targeted therapies for high-risk individuals (e.g., BRCA, PTEN, etc.).
You must register to access.
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 2 Chemoprevention
Open to view video.  |  58 minutes
Open to view video.  |  58 minutes Review chemopreventive clinical trials pertinent to individuals at high risk for developing cancer. Apply these data appropriately to individuals at genetic versus empiric high risk. Describe chemoprevention studies currently open for enrollment.
You must register to access.